Details

Autor(en) / Beteiligte

• Faria, Sofia Carolina Gonçalves

Titel

Baricitinib for the Treatment of Alopecia Areata

Ort / Verlag

ProQuest Dissertations & Theses

Erscheinungsjahr

2023

Link zum Volltext

• ProQuest

Quelle

ProQuest Dissertations & Theses A&I

Beschreibungen/Notizen

• Alopecia areata (AA) is a chronic, tissue-specific autoimmune disorder, characterized by non-scaring hair loss, with a global prevalence of approximately 2%. Typically, it affects a young population, with initial onset frequently occurring before age of 30 years. Even though the exact pathogenesis of AA remains unclear, the predominant hypothesis is the breakdown of the immune privilege (IP) of the hair follicle, resulting in increased self-antigen and MHC expression in the follicular epithelium. The relapsing nature of the disease negatively impacts patients’ quality of life and makes them susceptible to develop psychiatric comorbidities. Although many treatment modalities have been proposed, there are no currently available treatments able to induce and sustain disease remission. Traditional treatment modalities despite being widely used present limited results and high risk of adverse effects. Therefore, there is an unmet need for more effective and safer treatments. The recent insights into the pathophysiology of AA and its association with the JAK/STAT pathways, have led to the development of the JAK inhibitors, small molecular agents that block this intracellular signaling pathway. Baricitinib an orally administered, selective JAK1 and JAK 2 inhibitor is a promising alternative to the available treatments, already approved for the treatment of alopecia areata.